Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
$216.75
-$1.97(-1.10%)
At close: 4:00 PM EST
$216.75
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$164.39 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.38M
Market Cap
$392.16B
Enterprise Value$473.40B
Total Cash (Recent Filing)$5.67B
Total Debt (Recent Filing)$68.74B
Price to Earnings (P/E)167.4
Beta0.25
Next Earnings
Feb 04, 2026EPS Estimate
3.19Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)1.86
Shares Outstanding1,767,384,600
10 Day Avg. Volume6,281,119
30 Day Avg. Volume5,377,725
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)94.54
Price to Sales (P/S)5.58
P/FCF Ratio17.63
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue7.94
Enterprise Value/Gross Profit11.38
Enterprise Value/Ebitda37.00
Forecast
1Y Price Target
$254.06Price Target Upside17.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)14.27
Revenue Forecast (FY)$66.76B
Bulls Say, Bears Say
Bulls Say
Immunology Franchise StrengthSkyrizi and Rinvoq's sustained market share leadership across multiple markets supports continued strong sales growth and operating margin expansion driven by core immunology demand.
Indication Expansion And Pipeline UpsideRinvoq's potential approvals in additional inflammatory indications and progress in neuroscience and antibody‑drug conjugate programs could drive upside to consensus estimates.
Manufacturing Capacity InvestmentA large U.S. manufacturing expansion commitment strengthens supply resilience and could support long‑term growth and margin improvement through improved production capabilities.
Bears Say
Aesthetics Franchise WeaknessSoft consumer demand for dermal fillers and recent softness in the aesthetics business could offset gains from new product launches and weigh on near‑term revenue growth.
Emerging Competitive ThreatsNew rival therapies, including competing antibodies and potential oral IL‑23 entrants, create uncertainty for market share in key immunology indications.
Valuation RiskShares trading at the high end of historical valuation ranges limit upside and make future returns dependent on consistently strong execution.
AbbVie News
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $164.39 and its highest was $244.81 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $392.16B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Feb 04, 2026 which is in 18 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 31, 2025. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.766 by $0.094.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.87%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.19.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,384,600 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $1.86 in its last earnings report, beating expectations of $1.766. Following the earnings report the stock price went down -4.452%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$254.06 (17.21% Upside)
$254.06 (17.21% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 410.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.81%
12-Months-Change
Fundamentals
Return on Equity
138.53%
Trailing 12-Months
Asset Growth
-6.64%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie's earnings call reflects a strong overall performance with significant growth in key therapeutic areas like immunology and neuroscience. Financial results exceeded expectations, and the company raised its full-year outlook. However, challenges persist in the aesthetics segment and Humira's sales erosion due to biosimilar competition. Despite these challenges, the company's robust pipeline and increased R&D investment underline a positive long-term outlook.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$254.06
▲(17.21% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.79% Mutual Funds
― Other Institutional Investors
57.47% Public Companies and Individual Investors